-
Strange Price Action In Sarepta Therapeutics
Friday, May 20, 2016 - 11:39am | 199Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $0.71 (3.8 percent) in Friday's session. The pharmaceutical company whose future is tied to the approval of its main drug, Eteplirsen, had a strange unexplained move in pre-market trading. Around 6:30 a.m. ET, the issue...
-
Sarepta Therapeutics Surges 20% On No News
Friday, May 20, 2016 - 7:51am | 339Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by 20 percent at one point early Friday morning on no confirmed news reports. Sarepta's investor relations website showed no new updates. Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in...
-
Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval
Thursday, April 28, 2016 - 11:15am | 278Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by around 20 percent Thursday morning after The Street's biotech expert Adam Feuerstein penned an article titled "Why Sarepta Can Ultimately Win FDA Drug Approval." Shares of Sarepta were hard hit after a federal...
-
Strength In Sarepta: Why Today's Moves Were Predictable
Tuesday, April 26, 2016 - 5:26pm | 535Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower by $4.09 at $10.86 in Tuesday's session. The catalyst for the decline is likely a vote by the FDA against Duchenne Muscular Dystrophy drug, Eteplirsen. But in the face of this bearish news, PreMarket Prep hosts Joel Elconin and...
-
Eteplirsen Not Effective: Sarepta Therapeutics Plunges 50%
Tuesday, April 26, 2016 - 7:39am | 265Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged 50 percent early Tuesday morning after a federal advisory panel voted that eteplirsen, its drug for the treatment of Duchenne muscular dystrophy (DMD), was not effective. The U.S. Food and Drug Administration voted 6-7 against the...
-
The Street's Feuerstein Breaks Down Sarepta's 40% Plunge
Thursday, April 21, 2016 - 10:51am | 338Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 40 percent on Thursday after the U.S. Food and Drug Administration released briefing documents which consisted of an updated clinical review of the company's Duchenne muscular dystrophy drug, eteplirsen. According to The...
-
Sarepta Higher Off Positive Comments Regarding Eteplirsen
Monday, March 21, 2016 - 2:13pm | 118Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $3.24 (18 percent) at $21.24 in Monday's session. The catalyst for the rally is a letter circulating from Group of DMD doctors regarding the main drug in its pipeline, Eteplirsen. After a higher open, it retreated only a...
-
Sarepta Therapeutics Gives Up Gains Following Notable Tweet
Tuesday, February 23, 2016 - 3:29pm | 313Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher on heavy volume and hit an intra-day high of $15.74 Tuesday afternoon. Sarepta's gain was short-lived as the stock quickly gave up all gains and was trading lower by more than 2 percent mid-Tuesday afternoon. Investors and...
-
Sarepta Therapeutics Dropped 10% Following FDA News
Monday, February 8, 2016 - 2:01pm | 209Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 10 percent on Monday and hit a new 52-week low of $10.60 after the company received a notification from the U.S. Food and Drug Administration. The FDA told Sarepta Therapeutics that it requires additional time to complete its...
-
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Friday, January 22, 2016 - 4:38pm | 209Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by more than 3 percent on Friday, but have lost more than 60 percent after the FDA released a briefing document related to the company's eteplirsen. Related Link: Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen...
-
Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen
Friday, January 15, 2016 - 10:16am | 193Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged lower by more than 50 percent ahead of Friday's market open after the FDA released a briefing document related to the company's Eteplirsen. Sarepta Therapeutics is seeking accelerated approval for eteplirsen for patients with DMD...
-
Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling
Friday, November 20, 2015 - 11:19am | 502Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 30 percent Friday morning, while shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) lost more than 6 percent. The Wall Street Journal reported that BioMarin faces an FDA advisory committee next week to vote for approval or...
-
5 Biotech Stocks On Deck With The FDA
Tuesday, June 30, 2015 - 1:39pm | 482Read More...Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does...
-
Sell The News In Sarepta Therapeutics
Monday, June 29, 2015 - 1:09pm | 164Read More...Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were trading lower by $2.60 (9 percent) at $28.66 in Monday's session. The decline is taking place even though the company completed its NDA submission to...
-
Stocks Mixed Despite Better Than Expected GDP
Wednesday, July 30, 2014 - 4:43pm | 2929Read More...U.S. stocks were mixed as the Fed continued to wind down its monthly asset purchase program by another $10 billion. The Fed noted that the economy rebounded in the second quarter despite significant under-utilization remaining in the labor market. As such, the Fed noted, it will maintain a...
